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Background: The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases
resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study
outcome.
Methods: A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and
treatment of progressive disease were obtained for the 109 (CT n¼ 48, CT and CTX n¼ 61) patients with progressive disease at the
cut-off date for analysis of November 2012.
Results: The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of
patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P¼ 0.04). Further
treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based.
Twenty-two patients, 11 in each arm, received CTX as a further line agent.
Conclusions: Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of
disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease
control following liver surgery.
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Surgical resection of colorectal liver metastasis (CRLM) is feasible
in 10–20% of patients presenting with liver-only disease and
confers a five-year survival of 35–40% (Kanas et al, 2012).
Following resection disease progression is a challenge, occurring in
75% of patients (Nordlinger et al, 1996) of which half of the
recurrences are in the liver (Lorenz et al, 1998; Giacchetti et al, 1999;
Andre et al, 2004). Perioperative chemotherapy (CT) can reduce
the risk of relapse (Nordlinger et al, 2008) as well as obviating
surgery in those who progress rapidly because of poor biology, and
has become standard of care in many centres. The New EPOC
study sought to assess the benefit of adding cetuximab (CTX), an
antibody to the epidermal growth factor receptor, to standard
perioperative CT for patients with operable CRLM. Unexpectedly,
the addition of CTX resulted in a significantly shorter progression-
free survival (Primrose et al, 2014).
Following surgery for CRLM the most common site of first
treatment failure is the liver with the lung being second
(Nordlinger et al, 2008; de Jong et al, 2009). Data suggest that
the pattern of recurrence is relevant to outcome with lung only
recurrence possibly favouring a better prognosis (Govaert et al,
2014). In the context of significant progression-free intervals,
selected patients can expect improved survival with further lung
and liver resection (Luo et al, 2014). For those unsuitable for
additional surgery, further systemic treatment offers good disease
control, reflected in the favourable long-term survival for patients
presenting with CRLM (Nordlinger et al, 2013).
We have examined the pattern of treatment failure in the New
EPOC study to determine whether it can inform the unexpected
study outcome. Potential differences in post-progression therapy
may inform an important secondary end point such as overall
survival.
MATERIALS AND METHODS
Study design, treatments and objectives. The New EPOC study
(ISRCTN 22944367) design, eligibility criteria and treatment
regimens have been described previously (Primrose et al, 2014).
This was a multi-centre prospective randomised open label phase
III controlled trial. The study was approved by the South West
Research Ethics Committee and all patients provided written
informed consent. Patients with KRAS exon 2 wild-type resectable
or suboptimally resectable colorectal liver metastases were
randomised 1 : 1 to receive CT with or without CTX before and
after liver resection. The primary objective was to determine a
difference in progression-free survival between the treatment
groups. The trial was closed to recruitment on 1 November 2012
when protocol-defined futility criteria were met. The focus of the
present analysis is to ascertain detailed data regarding the patients
with progressive disease.
Data collection. Gender, age, site of primary disease, lymph node
involvement, serum CEA level and dates of progression and death
had already been obtained as part of New EPOC. For the 109
patients (CT alone group¼ 48, CT plus CTX group¼ 61) with
progressive disease at the cut-off date for analysis of 1 November
2012, additional data regarding first site(s) of progressive disease
and treatments undertaken for progressive disease were obtained
using case report forms. One patient, who was previously reported
as having progressed before the data cut-off, has since been
confirmed as not having progressive disease. An additional 13
patients (CT alone group n¼ 8, CT plus CTX group n¼ 5) died
but had not progressed.
Post-progression survival was defined as the time from date of
progression to death. Patients still alive were censored at their date
of last follow-up or 1 November 2012, whichever was earlier, so as
not to release data that are at present immature but that will
contribute to a final analysis of the trial in the future.
Statistical analysis. The comparison of post-progression survival
between the treatment groups was done with Cox proportional-
hazards regression and Kaplan–Meier curves. All analyses were
done on a modified intention-to-treat basis, including all patients
with known KRAS exon 2 wild-type genotype who had confirmed
progressive disease at the cut-off date for analysis of 1 November
2012. Only the analyses on further lines of CT were pre-defined.
SAS (version 9.2 or above, SAS Institute Inc., Cary, NC, USA) and
STATA (version 11 or above, StataCorp LP, College Station, TX,
USA) were used for all analyses.
RESULTS
The clinico-pathologic features of the 110 patients with progressive
disease identified before the cut-off for analysis of 1 November 2012
are shown in table one as previously described (Primrose et al, 2014).
The baseline and clinico-pathologic characteristics of the patients
with progressive disease were similar between the groups (Table 1).
Of the 109 patients with progression events, the majority
occurred after surgery (CT group 27% (13/48) vs 73% (35/48),
CT and CTX group 25% (15/61) vs 75% (46/61); Table 2).
Approximately half of all progression events involved the liver only
(CT 60% (29/48), CTX group 49% (30/61)). When this analysis is
restricted to those patients with post- rather than pre-operative
progression, the same trend is apparent (CT 54% (19/35), CTX
48% (22/46)). Other single sites of progressive disease were
similarly well balanced between the two groups of the trial,
although a higher proportion of patients in the CTX group had
multiple sites of progressive disease (CT 8%, 4/48; CTX 23%,
14/61, difference 15% 95% CI 2.0%–28.1% P¼ 0.04).
Over three quarters of patients (84/109) were reported to have
undergone further treatment(s) for progressive disease (CT 75%
(36/48); CTX 79% (48/61)). Of those the majority received further
CT (CT 58%, 28/48; CTX 67%, 41/61), however, 31% (15/48) in the
CT group and 23% (14/61) in the CTX group underwent surgical
treatment of progressive disease with curative intent (Table 3).
Four patients (4/48) in the CT group and six patients (6/61)
patients in the CTX group received ablative therapies for
progressive disease in the liver, lung or both. Radiotherapy was
used to treat progressive disease in 6% (3/48) of patients in the
CT group and 7% (4/61) in the CTX group. Twenty-seven percent
Table 1. Characteristics of all randomised KRAS wild-type










Male 29 (60%) 42 (69%)
Female 19 (40%) 19 (31%)
Number of metastases
1 metastasis 21 (44%) 29 (48%)
41 metastases 27 (56%) 31 (51%)
Missing 0 1 (2%)
Presentation of disease
Synchronous metastases 27 (56%) 33 (54%)
Non-synchronous metastases 21 (44%) 28 (46%)
Treatment regimen
CAPOX 14 (29%) 17 (28%)
OxMdG 28 (58%) 38 (62%)
IrMdG 6 (13%) 6 (10%)
aApproximate age at randomisation using year of birth.
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(13/48) in the CT group and 41% (25/61) in the CTX group
received CT alone as treatment for progressive disease.
Data were received on 69 patients (16 who had pre-operative
progression and 53 who had post-operative progression) that
received further CT for progressive disease (Table 4). The majority
of second-line therapy given was irinotecan-based without any
additional biological therapy. Twenty-two were given CTX as a
further line treatment: 11 following CT and 11 following CTX.
Four patients received CTX as a second line treatment for
progressive disease having had CT plus CTX as part of the trial.
Anti-vascular endothelial growth factor therapy was given as a
treatment for progressive disease to 26 patients: 7 in the CT group
and 19 in the CTX group.
Median follow-up post progression was 14.5 months (95% CI
5.4–19.6) in the CT alone group and 14.2 months (95% CI 6.3–
19.5) in the CT plus CTX group. The median post-progression
survival was 18.7 months (95% CI 13.1-not reached; Figure 1) in
the CT group compared with 15.9 months (95% CI 8.6–26.1) in the
CTX group (HR 1.69, 95% CI 0.86–3.34 P¼ 0.130). When this
analysis was restricted to those patients that underwent a R0
resection of the liver as part of the trial (29 in the CT group, 34 in
the CTX group), the median post-progression survival was 29.0
months (95% CI 16.5-not reached) in the CT group compared with
19.9 months (95%CI 13.2-not reached) in the CTX group (HR 2.07
95% CI 0.70–6.09 P¼ 0.187).
A total of 38 patients have had surgery or ablation with curative
intent for progressive disease. The post-progression survival of
these individuals was compared with those who did not receive
surgery or ablative therapy with curative intent for progressive
disease. Median follow-up post progression was 12.8 months (95%
CI 5.4–19.2) in the surgery/ablation with curative intent for
progressive disease group and 14.5 months (95% CI 6.0–24.0) in
the group with progressive disease not treated with curative intent.
The median post-progression survival was not reached in the
surgically/ablation treated group (lower limit of 95% CI 26.1
months; Figure 2) compared with 14.3 months (95% CI 8.4–17.6)
in the group not treated with curative intent for progressive disease
(HR 17.42, 95% CI 4.14–73.25, Po0.001).






Preoperative progression 13 15
Liver only 10 (77%) 8 (53%)
Lung only 1 (8%) 0
Locoregional only 0 1 (7%)
Peritoneal only 1 (8%) 1 (7%)
Nodal 0 0
Multi-site 0 5 (33%)
Unknowna 1 (8%) 0
Postoperative progression 35 46
Liver only 19 (54%) 22 (47%)
Lung only 8 (23%) 8 (17%)
Locoregional only 1 (3%) 3 (7%)
Peritoneal only 2 (6%) 0
Nodal 1 (3%) 4 (9%)
Multi-site 4 (11%) 9 (20%)
aPatient withdrew from trial at the time of progression.







Surgery 15 (31%) 14 (23%)
Liver resection 11 (23%)a 8 (13%)b
Lung resection 3 (6%) 3 (5%)
Liver and lung resection 1 (2%) 2 (3%)
Multivisceral resection 0 1 (2%)
Ablation 4 (8%) 5 (8%)
Liver ablation 3 (6%) 2 (3%)
Lung ablation 1 (2%) 1 (2%)
Liver and lung ablation 0 2 (3%)
aFive of these liver resections were performed for preoperative progression and as such
were the first liver resection these patients underwent.
bTwo of these liver resections were for preoperative progression and as such were the first
liver resection these patients underwent.







Type of 2nd line treatment 27 41
Oxaliplatin based 5 (19%) 5 (12%)
Irinotecan based 9 (33%) 17 (41%)
Fluropyrimidine only 2 (7%) 2 (5%)
Cetuximab based 8 (30%) 4 (10%)
Bevacizumab based 3 (11%) 12 (29%)
Aflibercept based 0 1 (2%)
Other 0 0
Type of 3rd line treatment 16 20
Oxaliplatin based 3 (19%) 4 (20%)
Irinotecan based 3 (19%) 3 (15%)
Fluropyrimidine only 2 (13%) 1 (5%)
Cetuximab based 2 (13%) 4 (20%)
Bevacizumab based 3 (19%) 4 (20%)
Aflibercept based 1 (6%) 1 (5%)




Type of 4th line treatment 4 7
Oxaliplatin based 0 1 (14%)
Irinotecan based 1 (25%) 0
Fluropyrimidine only 0 1 (14%)
Cetuximab based 1 (25%) 3 (43%)
Bevacizumab based 0 1 (14%)
Aflibercept based 0 0
Other 2 (50%) 1 (14%)
Data on further lines of chemotherapy received between October 2013 and May 2014.
Percentages are based on the number within each type of treatment line, as shown in the
‘Type of xth line treatment’.
Time to death from disease progression








































Figure 1. Kaplan–Meier curve of post-progression survival by
treatment group.
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DISCUSSION
This analysis demonstrates that the pattern of progression and
subsequent treatment for patients do not differ substantially
between the arms of the New EPOC study. There is one notable
difference, a significantly higher proportion of multi-site recur-
rences in the CTX group, although the numbers are modest.
In both arms of the study, the liver was the most frequent first site
of failure. This pattern of disease progression is much the same as
that observed in other studies including the original EPOC study
(Nordlinger et al, 2008; de Jong et al, 2009).
The incidence of progressive disease in the liver was comparable
between the two groups of the trial. This refutes the contention that
inadequate surgery or differential use of ablation was responsible
for the primary study outcome (Nordlinger et al, 2015; Primrose
et al, 2015). It also allays concerns regarding the possibility of
differential imaging being performed before trial entry. All patients
were managed in high-volume liver centres and while the trial
protocol only mandated computed tomography, the majority will
have had additional imaging performed. As the randomisation is
stratified by centre (hence MDT) bias is not possible. Indeed the
large majority of progression events were post surgery and the
greater proportion of multi-site progressions in the CT plus CTX
group is more in keeping with a failure of systemic disease control.
The majority of patients with disease progression received
additional off-trial treatments. The choice of further systemic
therapy is as expected for such a cohort and reasonably similar in
both groups. A number of patients received antibody therapies in
the second or subsequent lines of treatment which is in keeping
with their availability under the Cancer Drug Fund (introduced in
the UK in 2011). Those treated with CT alone as part of the trial
often received CTX post progression and indeed some that
received it on trial also received it following progression. This
pattern of post-progression treatment is consistent with standard
practice in the UK.
Progression-free survival is widely accepted as a surrogate for
overall survival in clinical trials of colorectal cancer (Giessen et al,
2013). It is however important to distinguish between curative and
palliative intent. For liver only progression, one-third of those that
progressed during the neoadjuvant phase of treatment went onto
have a potentially curative liver resection and a similar proportion
that progressed postoperatively underwent a further liver resection.
These data are in line with a published series suggesting that
approximately one-third of recurrences in the liver can be offered
repeat hepatectomy (Jones et al, 2012).
Overall this analysis demonstrates that a quarter of patients
went onto have further surgery with curative intent, predominantly
lung and/or liver resections. This was balanced between the groups.
Repeat liver surgery has been shown to be associated with
favourable survival outcomes (Petrowsky et al, 2002; Lam et al,
2013; Luo et al, 2014), and indeed the post-progression survival for
the cohort treated with curative intent looks most favourable,
although it is noteworthy that the period of follow-up available is
presently short. The relatively short follow-up (consequent in part
on premature study cessation) restricts the ability of these data to
inform whether the detrimental effect of CTX persists beyond
relapse and a final analysis will obviate these issues.
In summary, the present study demonstrates that the pattern of
failure associated with the addition of CTX to surgery and routine
CT for operable colorectal liver metastases is as expected for such a
cohort. The slightly higher proportion of multi-site recurrence in
the CT and CTX group is the only notable difference. The pattern
of disease progression seen is strongly suggestive of a systemic
failure consistent with micrometastatic disease rather than local
failure of disease control at the site of resection.
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Figure 2. Kaplan–Meier curve of post-progression survival according
to whether treatment of progressive disease was undertaken with
curative or palliative intent.
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